KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Equity Income (2024 - 2025)

Castle Biosciences (CSTL) has disclosed Equity Income for 2 consecutive years, with -$1.8 million as the latest value for Q4 2025.

  • Quarterly Equity Income fell 430.45% to -$1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 172.43% year-over-year, with the annual reading at $1.5 million for FY2025, 164.14% up from the prior year.
  • Equity Income hit -$1.8 million in Q4 2025 for Castle Biosciences, down from $3.6 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $3.6 million in Q3 2025 to a low of -$1.8 million in Q4 2025.